News · 26 weeks24-86%
2025-12-142026-06-07
Mix1290d
- Market5(42%)
- SEC Filings4(33%)
- Other2(17%)
- Insider1(8%)
Latest news
25 items- NEWSenVVeno Medical to Participate in the Virtual Investor Closing Bell SeriesLive video webcast with Robert Berman, Chief Executive Officer of enVVeno Medical, on Tuesday, June 9that 4:00 PM ETRegister here IRVINE, CA / ACCESS Newswire / June 2, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that Robert Berman, Chief Executive Officer of enVVeno Medical will participate in a Virtual Investor Closing Bell event on Tuesday, June 9, 2026 at 4:00 PM ET.As part of the event, Mr. Berman will discuss the Company's recently reported IDE approval of its enVVe® System, marking a first-ever FDA IDE approval for a U.S. pivotal study of a non-surgical
- SECAmendment: SEC Form SCHEDULE 13G/A filed by enVVeno Medical CorporationSCHEDULE 13G/A - enVVeno Medical Corp (0001661053) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by enVVeno Medical CorporationSCHEDULE 13G/A - enVVeno Medical Corp (0001661053) (Subject)
- NEWSenVVeno Medical Discusses FDA IDE Approval in Virtual Investor "What This Means" SegmentFirst-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-surgical Replacement Venous ValveIDE approval positions enVVeno to advance what could become the first effective treatment option for the approximately 3 million U.S. patients suffering from DVIWatch the "What This Means" video here IRVINE, CA / ACCESS Newswire / May 12, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced that Robert Berman, Chief Executive Officer of enVVeno Medical participated in a Virtual Investor "What This Means" segment. As part of the segment, Mr. Berman discussed the Company's recent news announcing the U.S. Food and Drug Administration's (FDA) first-ev
- NEWSenVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe SystemCompany ended the first quarter with approximately $25 million in cash and investmentsCapital on hand should fund operations through multiple key milestones into Q3 2027Company recently received FDA IDE approval to commence TAVVE U.S. Pivotal Study for non-surgical replacement venous valve, enVVe SystemTAVVE site selection is underway with patient enrollment expected to commence later this year IRVINE, CA / ACCESS Newswire / May 7, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today reported financial results for the first quarter 2026, ending the quarter with approximately $25 million in cash and investments and confirming the Company's strategic foc
- SECSEC Form 10-Q filed by enVVeno Medical Corporation10-Q - enVVeno Medical Corp (0001661053) (Filer)
- SECenVVeno Medical Corporation filed SEC Form 8-K: Other Events, Results of Operations and Financial Condition, Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits8-K - enVVeno Medical Corp (0001661053) (Filer)
- NEWSenVVeno Medical Receives First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-Surgical Replacement Venous ValveFirst-in-Class enVVe system to be evaluated in TAVVE U.S. Pivotal TrialClinical site activation and patient enrollment expected to commence later this yearLarge unmet clinical need for approximately 3 million U.S. patients with severe deep Chronic Venous InsufficiencyPotential multi-billion-dollar untapped U.S. marketCompany has approximately $25 million in cash and investments to fund operations into Q3 2027 IRVINE, CA / ACCESS Newswire / April 29, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that the U.S. Food and Drug Administration (FDA) has awarded the Comp
- NEWSenVVeno Medical Reports Full Year 2025 Financial Results and Highlights Strategic Advancement of enVVe(R) SystemCompany accelerated development of the enVVe® System, completing pre-clinical studies and progressing toward a 2026 pivotal trial initiationStrong financial position expected to provide an operating runway into mid-2027 through the achievement of key clinical milestonesIRVINE, CA / ACCESS Newswire / March 27, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced financial results for the year ended December 31, 2025 and provided a corporate update highlighting its strategic focus on the development of its next-generation enVVe® System.Robert Berman, Chief Executive Officer of enVVeno Medical Corporation, stated, "2025 represented a significant
- SECSEC Form S-8 filed by enVVeno Medical CorporationS-8 - enVVeno Medical Corp (0001661053) (Filer)
- SECSEC Form 10-K filed by enVVeno Medical Corporation10-K - enVVeno Medical Corp (0001661053) (Filer)
- INSIDERDirector Duhay Francis sold $1,613 worth of shares (140 units at $11.52), decreasing direct ownership by 5% to 2,502 units (SEC Form 4)4 - enVVeno Medical Corp (0001661053) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by enVVeno Medical CorporationSCHEDULE 13G/A - enVVeno Medical Corp (0001661053) (Subject)
- SECenVVeno Medical Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - enVVeno Medical Corp (0001661053) (Filer)
- NEWSenVVeno Medical Regains Compliance with Nasdaq Minimum Bid Price RequirementCompany achieves minimum $1.00 closing bid for 10 consecutive business days; Nasdaq confirms matter is closedReports Cash and Investments of approximately $28 million as of the Year Ended December 31, 2025IRVINE, CA / ACCESS Newswire / February 4, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced that it has received formal notice from the Listings Qualifications staff of The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. Nasdaq confirmed that for the last 10 consecutive business days, from January 20, 2026 through Febru
- SECenVVeno Medical Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year8-K - enVVeno Medical Corp (0001661053) (Filer)
- NEWSenVVeno Medical Announces Reverse Stock SplitIRVINE, CA / ACCESS Newswire / January 15, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced that the Company's Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1 for 35 (the "Reverse Stock Split"). The Reverse Stock Split will become effective at 12:01 a.m. Eastern time on January 20, 2026 and the Company's common stock will open for trading on The Nasdaq Capital Market on a post-split basis on January 20, 2026 under the Company's existing trading symbol "NVNO". At such time, the Company's common stock will also commence trading under a new CUSIP number 29415J205."The Reverse Stock Split, w
- INSIDERSEC Form 4 filed by Chief Executive Officer Berman Robert Andrew4 - enVVeno Medical Corp (0001661053) (Issuer)
- INSIDERSEC Form 4 filed by Chief Technology Officer Alavi Hamed4 - enVVeno Medical Corp (0001661053) (Issuer)
- INSIDERSEC Form 4 filed by SVP & Chief Medical Officer Glickman Marc H.4 - enVVeno Medical Corp (0001661053) (Issuer)
- INSIDERSEC Form 4 filed by Director Duhay Francis4 - enVVeno Medical Corp (0001661053) (Issuer)
- INSIDERSEC Form 4 filed by Director Gray Robert4 - enVVeno Medical Corp (0001661053) (Issuer)
- INSIDERSEC Form 4 filed by Director Jenusaitis Matthew4 - enVVeno Medical Corp (0001661053) (Issuer)
- INSIDERSEC Form 4 filed by Director Shrivastava Sanjay4 - enVVeno Medical Corp (0001661053) (Issuer)
- INSIDERDirector Duhay Francis sold $1,742 worth of shares (4,900 units at $0.36), decreasing direct ownership by 5% to 92,544 units (SEC Form 4)4 - enVVeno Medical Corp (0001661053) (Issuer)
NVNO FAQ
6 questionsWhat does enVVeno Medical Corporation do?
enVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based devices to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of severe deep venous chronic venous insufficiency. Its VenoValve is implanted in the femoral vein and works as a replacement venous valve to reduce reflux and venous hypertension, as well as to restore proper directional blood flow back to the heart. The company was formerly known as Hancock Jaffe...Where does NVNO stock trade?
enVVeno Medical Corporation (NVNO) is listed on NASDAQ.What sector and industry is NVNO in?
enVVeno Medical Corporation operates in the Health Care sector, Medical/Dental Instruments industry.When did enVVeno Medical Corporation go public?
enVVeno Medical Corporation (NVNO) completed its IPO in 2018.What companies are similar to NVNO?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare NVNO side-by-side with any of them on Quantisnow.How can I track NVNO on Quantisnow?
Quantisnow aggregates enVVeno Medical Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NVNO to receive live email and push alerts on every new disclosure.